Wed, Jul 22, 2026 | Updated 06:08 IST
May 12, 2022
Seoul [South Korea], May 12 (ANI/Global Economic): NeoImmuneTech said on the 11th that it has obtained the approval for a phase 2 clinical trial plan that concomitant administration of US Merck's immune checkpoint inhibitor Keytruda and its T-cell amplifier NT-I7 to patients with glioblastoma from the United States Food & Drug Administration (US FDA).
Seoul [South Korea], May 12 (ANI/Global Economic): South Korea's COVID-19 daily cases were 43,925 on Tuesday. New deaths were 29, falling below 30 in 86 days.
More News
New Delhi [India], May 12 : Prime Minister Narendra Modi will pay an official visit to Lumbini next...
Beijing [China], May 12 : Chinese President Xi Jinping has sent a congratulatory message to Ferdinand Romualdez Marcos...
Kabul [Afghanistan], May 12 : The European Union Ambassador to Afghanistan, Andreas von Brand, has expressed concerns over...